Synthesis and Biological Activity of Novel Aromatic Aminopropyl Lactams in Two Cancer Cell Models
Open Access
- 26 July 2026
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 21 (14) , e70394
Abstract
The development of new therapeutic agents for glioblastoma and hepatocellular carcinoma (HCC) remains a priority due to poor prognosis, limited treatment options, and high recurrence rates. Herein, we report a one‐pot synthesis of aromatic aminopropyl lactams (ArAPLs) via hydrolysis of bicyclic amidines (DBN, DBU), followed by reductive amination with aromatic aldehydes. These compounds were designed to target histamine H 3 receptors (H 3 R), which are often overexpressed in these malignancies. Docking studies suggested that compounds 3a and 4a may act as H 3 R antagonists, showing favorable binding through hydrophobic and hydrogen‐bonding interactions. Biological evaluation identified 3a and 4a as the most promising compounds, exhibiting micromolar antiproliferative activity in glioblastoma and HCC cell models. Compound 3a showed the best balance between potency and selectivity, including activity in 3D spheroid models and modulation of cell cycle‐related markers. In coculture systems, spheroids displayed reduced size and density, although a slight increase in viability was observed, particularly with 4a . Variations in peripheral cell layers suggest a role for macrophage behavior. Overall, these findings support the cytotoxic potential of ArAPLs, although further studies are required to confirm their role as H 3 R antagonists.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (UI/BD/151278/2021)
- Fundação para a Ciência e a Tecnologia (UID/50006/2025)
- Fundação para a Ciência e a Tecnologia (UID/PRR/50006/2025)
- Fundação para a Ciência e a Tecnologia (UID/04378/2025)
- Fundação para a Ciência e a Tecnologia (LA/P/0008/2020)
- Fundação para a Ciência e a Tecnologia (UID/PRR/04378/2025)
- Fundação para a Ciência e a Tecnologia (LA/P/0140/2020)
- Fundação para a Ciência e a Tecnologia (2022.09845.BD)
This publication has 50 references indexed in Scilit:
- Histamine H3 receptor: an emerging target for cancer therapy?Inflammation Research, 2025
- Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentialsBiomedicine & Pharmacotherapy, 2024
- Pitolisant: Pediatric First ApprovalPediatric Drugs, 2023
- Structural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H3 receptor ligandsBioorganic Chemistry, 2019
- Synthesis and evaluation of histamine H3 receptor ligand based on lactam scaffold as agents for treating neuropathic painBioorganic & Medicinal Chemistry Letters, 2019
- Pitolisant: First Global ApprovalDrugs, 2016
- Synthesis of potentially bioactive PABA-related N-(aminoalkyl)lactamic amino acids and esters via selective SNAr reactionsAmino Acids, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- The histamine H3 receptor as a therapeutic drug target for CNS disordersDrug Discovery Today, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009